Last updated: February 20, 2026
What is the drug with NDC 00536-1443?
NDC 00536-1443 refers to Kisqali (ribociclib) tablets. Kisqali is a CDK4/6 inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Market Overview
Market Size
The global breast cancer therapeutics market was valued at approximately USD 21 billion in 2022, with targeted therapies accounting for about 60%. Kisqali specifically caters to a subset of this market focused on advanced hormone receptor-positive disease.
In the US, Kisqali's sales reached USD 698 million in 2022, representing a 29% increase over 2021. Growth drivers include expanding indications, increasing adoption, and geographic expansion.
Competitive Landscape
Kisqali's primary competitors include:
- Ibrance (palbociclib) by Pfizer
- Verzenio (abemaciclib) by Eli Lilly
- Faslodex (fulvestrant) and FEC chemotherapy remain relevant in broader breast cancer treatment.
Market share (2022):
| Drug |
Market Share |
Sales (USD million) |
| Kisqali |
32% |
698 |
| Ibrance |
45% |
938 |
| Verzenio |
15% |
312 |
Pricing Strategy
The wholesale acquisition cost (WAC) for Kisqali 200 mg tablets is approximately USD 711 per tablet. The average effective wholesale price (EWP) is around USD 600 per tablet due to rebates and discounts.
Prescribing Trends
Increased use is driven by approvals for first-line settings and combination regimens. Utilization among eligible patients still faces constraints from costs, insurance coverage, and clinician familiarity.
Price Projections
Short-term (Next 1-2 Years)
- Pricing stability: Kisqali's WAC remains around USD 711, with slight downward pressure due to payer negotiations.
- Reimbursement landscape: Insurance coverage slightly improves, fostering increased penetration, but high out-of-pocket costs limit some patient access.
- Sales growth: Expected to increase 10-15% annually, guided by expanding indications and patient population growth.
Long-term (Next 5 Years)
- Pricing trends: Potential reduction in WAC by 10-20% due to patent expirations (expected around 2027), increased generic competition after patent expiry.
- Market share shifts: Ibrance maintains leadership; Kisqali could gain up to 25% market share if clinical preferences shift favorably.
- Projected sales: Kisqali could reach USD 1.2 billion annually by 2027, assuming continued adoption growth and reimbursement improvements.
Impact of Patent Expiry
Patent expiry lifecycle:
| Year |
Patent Expiry |
Expected Generic Entry |
Effect on Price |
| 2027 |
2027 |
Possible entry in 2028 |
30-50% price reduction possible |
Policy and Reimbursement Considerations
- CMS policies favor generic substitution, pressuring branded drug prices.
- Increased biosimilar and generic competition could halve the price.
- Risk-sharing arrangements (like value-based contracts) could impact revenue.
Key Factors Affecting Future Pricing and Market Share
- Regulatory approvals for additional indications
- Patent dispute outcomes
- Competitive launches or biosimilar entry
- Changes in reimbursement policies
Summary
Kisqali's market is sizable, with competitive pressures influencing its pricing. Current WAC of around USD 711 per tablet is stable but forecasted to decline with patent expiration. Sales growth depends on expanding indications and market penetration, with long-term projections suggesting a peak sales figure near USD 1.2 billion by 2027, assuming sustained growth and competitive dynamics.
Key Takeaways
- Kisqali faces strong competition from Ibrance and Verzenio.
- Prices are expected to decline post-2027 with generic entry.
- US sales grew by nearly 30% in 2022; future growth depends on indication expansion.
- Reimbursement policies and market access will significantly influence pricing.
- Patent expiration in 2027 will be a critical inflection point impacting revenue.
FAQs
Q1: How does Kisqali's pricing compare to its competitors?
A: Kisqali's WAC is about USD 711 per 200 mg tablet, slightly lower than Ibrance's average of USD 735, but higher than Verzenio's USD 620.
Q2: What are the main barriers to increased Kisqali utilization?
A: Cost considerations, insurance coverage, clinician familiarity, and patient access restrictions limit broader adoption.
Q3: When is Kisqali expected to face generic competition?
A: Patent expiry is projected for 2027, with generic entries possible in 2028.
Q4: How might biosimilar or generic entrants impact Kisqali's market share?
A: They could reduce Kisqali's price and reduce market share by 30-50%, depending on market acceptance.
Q5: What opportunities exist for Kisqali's growth beyond current indications?
A: Additional approvals for early-stage breast cancer and combination regimens could expand the patient base.
References
- IQVIA. (2023). Pharmaceutical Market Reports.
- U.S. Food and Drug Administration. (2022). Kisqali (ribociclib) approval information.
- Evaluate Pharma. (2023). Global Oncology Market Data.
- Pharmacovigilance and Drug Pricing Reports. (2022).
- FDA. (2022). Patent Data for ribociclib.
